HK1094166A1 - Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis - Google Patents

Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis

Info

Publication number
HK1094166A1
HK1094166A1 HK07101327.5A HK07101327A HK1094166A1 HK 1094166 A1 HK1094166 A1 HK 1094166A1 HK 07101327 A HK07101327 A HK 07101327A HK 1094166 A1 HK1094166 A1 HK 1094166A1
Authority
HK
Hong Kong
Prior art keywords
stem cells
neural stem
neurogenesis
hcg
luteinizing hormone
Prior art date
Application number
HK07101327.5A
Other languages
English (en)
Inventor
Samuel Weiss
Emeka Enwere
Linda Andersen
Christopher Gregg
Original Assignee
Stem Cell Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stem Cell Therapeutics Corp filed Critical Stem Cell Therapeutics Corp
Publication of HK1094166A1 publication Critical patent/HK1094166A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/31—Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/315—Prolactin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK07101327.5A 2004-02-13 2007-02-05 Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis HK1094166A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54491504P 2004-02-13 2004-02-13
PCT/CA2005/000184 WO2005077404A1 (fr) 2004-02-13 2005-02-14 Utilisation de l'hormone de luteinisation (lh) et de la gonadotropine chorionique (hcg) pour la proliferation de cellules souches neuronales et la neurogenese

Publications (1)

Publication Number Publication Date
HK1094166A1 true HK1094166A1 (en) 2007-03-23

Family

ID=34860512

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07101327.5A HK1094166A1 (en) 2004-02-13 2007-02-05 Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis

Country Status (9)

Country Link
US (3) US7846898B2 (fr)
EP (1) EP1740202B1 (fr)
JP (1) JP4990634B2 (fr)
AT (1) ATE556716T1 (fr)
AU (2) AU2005211847B2 (fr)
CA (1) CA2556266A1 (fr)
ES (1) ES2392282T3 (fr)
HK (1) HK1094166A1 (fr)
WO (1) WO2005077404A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002325712C1 (en) * 2001-08-30 2008-07-31 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
CA2460184A1 (fr) 2001-09-14 2003-03-27 Stem Cell Therapeutics Inc. Augmentation du nombre de cellules souche neuronales induites par la prolactine
US20030054551A1 (en) * 2001-09-18 2003-03-20 Stem Cell Therapeutics Inc. Effect of growth hormone and IGF-1 on neural stem cells
EP1546198A1 (fr) * 2002-07-31 2005-06-29 Stem Cell Therapeutics Inc. Procede d'amelioration de la proliferation, de la differentiation et de la survie de cellules souches neurales au moyen du polypeptide d'activation d'adenylate cyclase hypophysaire (pacap)
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
WO2005077404A1 (fr) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Utilisation de l'hormone de luteinisation (lh) et de la gonadotropine chorionique (hcg) pour la proliferation de cellules souches neuronales et la neurogenese
KR20080074108A (ko) 2005-09-27 2008-08-12 스템 셀 테라퓨틱스 코포레이션 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식
AU2007229301B2 (en) * 2006-03-17 2013-08-01 Stem Cell Therapeutics Corp. Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
US8574567B2 (en) 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
EP2155860B1 (fr) 2007-05-03 2014-08-27 The Brigham and Women's Hospital, Inc. Cellules souches multipotentes et leurs utilisations
WO2012164137A1 (fr) 2011-05-30 2012-12-06 Fundación Investigación En Regeneración Del Sistema Nervioso Cellules mères et cellules de la souche neurale dérivées de la glie olfactive enveloppante, et leurs applications
WO2014179139A2 (fr) * 2013-04-30 2014-11-06 Albert Einstein College Of Medicine Of Yeshiva University Traitement d'effets du vieillissement par la gonadolibérine, la neurogenèse ou l'inhibition de ikk-β/nf-κβ dans le cerveau
US11439668B2 (en) 2014-05-23 2022-09-13 JangoBio, LLC Methods to differentiate stem cells into hormone-producing cells
US11253549B2 (en) 2014-05-23 2022-02-22 JangoBio, LLC Methods to rebalance the hypothalamic-pituitary-gonadal axis
US20240115662A1 (en) * 2021-03-02 2024-04-11 Wisconsin Alumni Research Foundation Methods of treating hypogonadotropic hypogonadism and cognition impairment following a traumatic brain injury

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4840896A (en) 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4902680A (en) * 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
JPH01180833A (ja) 1988-01-11 1989-07-18 Nippon Kayaku Co Ltd 血管新生剤
CA2345497A1 (fr) * 1988-10-28 1990-04-28 Genentech, Inc. Variantes de l'hormones de croissance et procede de fabrication des variantes de l'hormone de croissance
EP0441889A1 (fr) 1988-11-07 1991-08-21 Commission des Communautés Européennes Hormone de croissance humaine modifiee
US5128242A (en) 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity
US5198542A (en) 1989-06-20 1993-03-30 Takeda Chemical Industries, Inc. Dna encoding a pitvitary adenylate cyclase activating protein and use thereof
US6329508B1 (en) * 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
EP0467279A3 (en) 1990-07-18 1992-08-05 Takeda Chemical Industries, Ltd. Polypeptides having c-amp producing activity
US5521069A (en) 1990-08-10 1996-05-28 Takeda Chemical Industries, Ltd. Genomic DNA exons having exons encoding human pituitary adenylate cyclase activity peptide with 38 amino acids residues(PACAP38) and a promoter thereof
US5189179A (en) * 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
US5231178A (en) 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
US5723115A (en) * 1991-05-02 1998-03-03 W. Alton Jones Cell Science Center, Inc. Inhibition of adipose tissue development and obesity
US5767215A (en) 1991-05-09 1998-06-16 Borealis Holding A/S Coarse-grained polyolefin, its production method and a catalyst used in the method
US6429186B1 (en) * 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
JP3417558B2 (ja) 1991-05-10 2003-06-16 ジェネンテク，インコーポレイテッド 配位子作用薬および拮抗薬の選択
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US6294346B1 (en) * 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
DE69233061T3 (de) 1991-07-08 2008-07-10 Neurospheres Holding Ltd., Calgary Auf wachstumsfaktoren reagierende neurale vorläuferzellen, die in vitro vermehrt werden können.
US5980885A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
WO1993003757A1 (fr) * 1991-08-16 1993-03-04 Chiron Corporation Muteines du facteur de croissance epidermique (fce) presentant une meilleure liaison a un ph faible
US5623050A (en) * 1991-08-22 1997-04-22 Takeda Chemical Industries, Ltd. Stable polypeptides having c-AMP production enhancing activity and the use thereof
US5253648A (en) * 1991-10-11 1993-10-19 Spacelabs Medical, Inc. Method and apparatus for excluding artifacts from automatic blood pressure measurements
US5239105A (en) * 1992-01-30 1993-08-24 The Dow Chemical Company Catalytic formation of diarylcarbonates
JPH07508025A (ja) 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
AU683023B2 (en) 1992-10-16 1997-10-30 Neurospheres Holdings Ltd Remyelination using neural stem cells
JPH08502652A (ja) 1992-10-28 1996-03-26 ニューロスフィアーズ リミテッド 生物学的因子と神経幹細胞
US5877169A (en) * 1993-11-05 1999-03-02 University Of Florida Research Foundation, Inc. Methods of treatment of ischemic damage
DK0728194T3 (da) * 1993-11-09 2003-04-22 Neurospheres Holdings Ltd In situ modifikation og manipulation af stamceller fra centralnervesystemet.
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US6399316B1 (en) 1994-02-25 2002-06-04 Takeda Chemical Industries, Ltd. PACAP receptor protein, method for preparing said protein, and use thereof
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US6239105B1 (en) 1994-03-31 2001-05-29 Barbara A. Brewitt Homeopathic preparations of purified growth hormone
WO1995029690A1 (fr) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Peptides biologiquement actifs et procedes permettant leur identification
US5858747A (en) 1994-07-20 1999-01-12 Cytotherapeutics, Inc. Control of cell growth in a bioartificial organ with extracellular matrix coated microcarriers
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US6680295B1 (en) 1994-09-22 2004-01-20 The Administrators Of The Tulane Educational Fund Method and pharmaceutical composition for prevention and treatment of brain damage
JPH10505863A (ja) 1994-09-22 1998-06-09 ジ・アドミニストレーターズ・オブ・ザ・チューレン・エデュケイショナル・ファンド 脳障害の予防および治療のための方法および医薬組成物
JPH10509592A (ja) 1994-11-14 1998-09-22 ニューロスフィアーズ ホウルディングス リミテッド 神経幹細胞増殖調節
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
AU6163196A (en) 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
US5547993A (en) * 1995-10-24 1996-08-20 Mitsubishi Chemical Corporation Therapeutic agent for glaucoma
US6346390B1 (en) * 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
US6017533A (en) 1996-04-25 2000-01-25 Shiseido Company, Ltd. Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
AU3492497A (en) 1996-06-21 1998-01-07 Arris Pharmaceutical Corporation Bivalent molecules that form an activating complex with an erythropoietin receptor
IT1284876B1 (it) 1996-08-07 1998-05-22 Applied Research Systems Hcg come inibitore della collagenasi
US6583109B1 (en) * 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
CA2301693A1 (fr) 1997-09-19 1999-04-01 Klaus Unsicker Cytokines ayant une activite neurotrophique
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
AU739173B2 (en) * 1997-10-31 2001-10-04 Ligand Pharmaceuticals Incorporated Novel metal complexes
TW445295B (en) * 1997-12-31 2001-07-11 Shiu Li Wei Expression vector pcDNA3.1-HC for human erythropoietin, BHK-21 host cell line transformed therewith, and production of human erythropoietin using the transformed cell
US6812027B2 (en) 1998-03-25 2004-11-02 Cornell Research Foundation, Inc. Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
US6242563B1 (en) * 1998-07-20 2001-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Peptide analogues
DE69941708D1 (de) 1998-07-20 2010-01-07 Ipsen Pharma Pacap-peptidanaloga
AU757907B2 (en) 1998-09-03 2003-03-13 Neuren Pharmaceuticals Limited Neuroprotection
SE9804064D0 (sv) 1998-11-25 1998-11-25 A & Science Invest Ab Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
FR2794473B1 (fr) * 1999-06-03 2003-09-26 Centre Nat Rech Scient Procede de multiplication de cellules souches
US6618698B1 (en) * 1999-08-12 2003-09-09 Quickturn Design Systems, Inc. Clustered processors in an emulation engine
WO2001028574A2 (fr) 1999-10-20 2001-04-26 Stem Cells, Inc. Procedes d'induction de la proliferation et la migration in vivo de cellules progenitrices transplantees dans le cerveau
US6395546B1 (en) 2000-02-01 2002-05-28 Neurogeneration, Inc. Generation of dopaminergic neurons from human nervous system stem cells
KR100358754B1 (ko) 2000-02-14 2002-11-07 대한민국 인간의 조혈촉진제 생산을 위한 형질전환 돼지를 생산하는방법 및 그 형질전환 돼지
US7259146B2 (en) * 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
CA2377666A1 (fr) * 2000-07-18 2002-01-24 Minoru Takebe Substance de renforcement des cellules souches
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
CN1486204A (zh) 2001-01-12 2004-03-31 ������˹ҩƷ��˾ 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物
AU2002338436A1 (en) 2001-04-25 2002-11-05 Hernan F. Acevedo Hcg formulation
US6740163B1 (en) 2001-06-15 2004-05-25 Seagate Technology Llc Photoresist recirculation and viscosity control for dip coating applications
AU2002315336A1 (en) 2001-06-18 2003-01-02 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5ht-1a agonists
CA2364095C (fr) 2001-07-20 2011-07-12 Neurostasis, Inc Production de cellules gliales radiales
AU2002325712C1 (en) * 2001-08-30 2008-07-31 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
CA2460184A1 (fr) 2001-09-14 2003-03-27 Stem Cell Therapeutics Inc. Augmentation du nombre de cellules souche neuronales induites par la prolactine
US20030054551A1 (en) 2001-09-18 2003-03-20 Stem Cell Therapeutics Inc. Effect of growth hormone and IGF-1 on neural stem cells
US7037504B2 (en) 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
ITPR20010072A1 (it) 2001-10-26 2003-04-26 Firaco Srl Apparato e procedimento di sicurezza per veicoli di trasporto, in particolare aeromobili.
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
EP1507551A2 (fr) 2002-05-03 2005-02-23 Neuronova AB Role fonctionnel et utilisation therapeutique potentielle de pacap, vip et maxadilan en rapport avec des cellules progenitrices ou souches neuronales chez l'adulte
US7704737B2 (en) 2002-07-30 2010-04-27 Stem Cell Therapeutics Inc. Oligodendrocyte production from multipotent neural stem cells
EP1546198A1 (fr) 2002-07-31 2005-06-29 Stem Cell Therapeutics Inc. Procede d'amelioration de la proliferation, de la differentiation et de la survie de cellules souches neurales au moyen du polypeptide d'activation d'adenylate cyclase hypophysaire (pacap)
WO2004011021A1 (fr) 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Procede permettant d'accroitre et/ou d'induire une migration neuronale au moyen de l'erythropoietine
AU2003280117B2 (en) * 2002-11-20 2009-09-10 Newron Sweden Ab Compounds and methods for increasing neurogenesis
AU2004226372A1 (en) * 2003-03-27 2004-10-14 Janssen Pharmaceutica N.V. Use of erythropoietin in stroke recovery
US20070111932A1 (en) 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
WO2005077404A1 (fr) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Utilisation de l'hormone de luteinisation (lh) et de la gonadotropine chorionique (hcg) pour la proliferation de cellules souches neuronales et la neurogenese
CA2582567A1 (fr) * 2004-10-07 2006-04-13 Stem Cell Therapeutics Corp. Stimulation de la proliferation de cellules souches pluripotentes par administration de composes associes a la gestation
KR20080074108A (ko) 2005-09-27 2008-08-12 스템 셀 테라퓨틱스 코포레이션 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식
AU2007229301B2 (en) * 2006-03-17 2013-08-01 Stem Cell Therapeutics Corp. Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
US20100047233A1 (en) * 2006-12-18 2010-02-25 Smith Mark A Treatment of post-menopausal and post-hysterectomy mediated cognitive disorders
US20100028361A1 (en) * 2006-12-19 2010-02-04 Smith Mark A Brain-derived gonadotropins and cognition
US20080286234A1 (en) * 2007-05-15 2008-11-20 Eyink Daniel A Method for treating demyelinating diseases
EP2217252A2 (fr) 2007-10-29 2010-08-18 Hadasit Medical Research Services & Development Limited Précurseurs neuraux dérivés de cellules souches humaines pour le traitement de maladies auto-immunes du système nerveux central
EP2297302A4 (fr) 2008-05-13 2013-05-15 Univ Queensland Procédé d induction de la prolifération et/ou la différenciation de cellules précurseurs neurales par introduction de prolactine ou wnt3a pour activer des cellules précurseurs neurales latentes

Also Published As

Publication number Publication date
WO2005077404A1 (fr) 2005-08-25
EP1740202B1 (fr) 2012-05-09
US20110178009A1 (en) 2011-07-21
EP1740202A1 (fr) 2007-01-10
US8435949B2 (en) 2013-05-07
EP1740202A4 (fr) 2009-07-08
AU2011202404A1 (en) 2011-06-16
US20120244111A1 (en) 2012-09-27
ES2392282T3 (es) 2012-12-07
US20050245436A1 (en) 2005-11-03
AU2005211847A1 (en) 2005-08-25
AU2005211847B2 (en) 2011-02-24
JP4990634B2 (ja) 2012-08-01
US8217002B2 (en) 2012-07-10
ATE556716T1 (de) 2012-05-15
CA2556266A1 (fr) 2005-08-25
JP2007522153A (ja) 2007-08-09
US7846898B2 (en) 2010-12-07

Similar Documents

Publication Publication Date Title
HK1094166A1 (en) Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
Zhang et al. Electro-acupuncture attenuates the mice premature ovarian failure via mediating PI3K/AKT/mTOR pathway
Wang et al. GDNF-pretreatment enhances the survival of neural stem cells following transplantation in a rat model of Parkinson's disease
Chakraborty et al. NK cells, hypoxia and trophoblast cell differentiation
Stevenson et al. Information theory and the neuropeptidergic regulation of seasonal reproduction in mammals and birds
Propst et al. Low-dose human chorionic gonadotropin may improve in vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration
WO2007106986A8 (fr) Régimes de dosage de lh ou hcg et epo pour le traitement de troubles neurologiques
Christophidis et al. Growth hormone receptor immunoreactivity is increased in the subventricular zone of juvenile rat brain after focal ischemia: A potential role for growth hormone in injury-induced neurogenesis
WO2003024471A3 (fr) Effet de l'hormone de croissance et de l'igf-1 sur les cellules souches neuronales
Qu et al. Transcutaneous electrical acupoint stimulation improves the outcomes of in vitro fertilization: a prospective, randomized and controlled study
Zheng et al. Transplantation of multipotent astrocytic stem cells into a rat model of neonatal hypoxic–ischemic encephalopathy
Hafen et al. Anatomy, smooth muscle
Matz et al. Administration of secretome from human placental stem cell‐conditioned media improves recovery of erectile function in the pelvic neurovascular injury model
Kozłowska et al. Distribution and chemical coding of sensory neurons innervating the skin of the porcine hindlimb
Lin et al. Increased expression of vasoactive intestinal polypeptide in cultured myenteric neurons from adult rat small intestine
Willems et al. Pituitary cell differentiation from stem cells and other cells: toward restorative therapy for hypopituitarism?
Taitson et al. Treating male infertility
Jansson et al. Region specific hypothalamic neuronal activation and endothelial cell proliferation in response to electroconvulsive seizures
Abbas et al. Melatonin along with eCG improves fresh semen quality and plasma concentrations of melatonin and testosterone during non-breeding season in Beetal bucks
Zhu et al. Therapeutic potential of human umbilical cord blood mesenchymal stem cells on erectile function in rats with cavernous nerve injury
Yoon et al. Projection patterns of lateral hypothalamic, cocaine-and amphetamine-regulated transcript (CART) neurons to the dorsal raphe and/or the locus coeruleus in the rat
Almahbobi et al. Three-dimensional image analysis to quantify the temporo-spacial expression of cellular receptors
Levine An introduction to neuroendocrine systems
Anthony Endocrinology of reproduction in bats: central control
Bulut et al. Crosstalk between kisspeptin and gonadotropin-inhibitory hormone in the silence of puberty: preclinical evidence from a calcium signaling study

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160214